Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Mar Drugs ; 15(10)2017 Oct 17.
Artigo em Inglês | MEDLINE | ID: mdl-29039762

RESUMO

A large diversity of 2-aminoimidazolone alkaloids is produced by various marine invertebrates, especially by the marine Calcareous sponges Leucetta and Clathrina. The phylogeny of these sponges and the wide scope of 2-aminoimidazolone alkaloids they produce are reviewed in this article. The origin (invertebrate cells, associated microorganisms, or filtered plankton), physiological functions, and natural molecular targets of these alkaloids are largely unknown. Following the identification of leucettamine B as an inhibitor of selected protein kinases, we synthesized a family of analogues, collectively named leucettines, as potent inhibitors of DYRKs (dual-specificity, tyrosine phosphorylation regulated kinases) and CLKs (cdc2-like kinases) and potential pharmacological leads for the treatment of several diseases, including Alzheimer's disease and Down syndrome. We assembled a small library of marine sponge- and ascidian-derived 2-aminoimidazolone alkaloids, along with several synthetic analogues, and tested them on a panel of mammalian and protozoan kinases. Polyandrocarpamines A and B were found to be potent and selective inhibitors of DYRKs and CLKs. They inhibited cyclin D1 phosphorylation on a DYRK1A phosphosite in cultured cells. 2-Aminoimidazolones thus represent a promising chemical scaffold for the design of potential therapeutic drug candidates acting as specific inhibitors of disease-relevant kinases, and possibly other disease-relevant targets.


Assuntos
Alcaloides/farmacologia , Imidazóis/farmacologia , Poríferos/química , Inibidores de Proteínas Quinases/farmacologia , Proteínas Serina-Treonina Quinases/antagonistas & inibidores , Proteínas Tirosina Quinases/antagonistas & inibidores , Urocordados/química , Alcaloides/síntese química , Alcaloides/uso terapêutico , Doença de Alzheimer/tratamento farmacológico , Aminas/síntese química , Aminas/farmacologia , Aminas/uso terapêutico , Animais , Antiprotozoários/síntese química , Antiprotozoários/farmacologia , Antiprotozoários/uso terapêutico , Síndrome de Down/tratamento farmacológico , Humanos , Imidazóis/síntese química , Imidazóis/química , Imidazóis/uso terapêutico , Fosforilação , Filogenia , Poríferos/genética , Inibidores de Proteínas Quinases/síntese química , Inibidores de Proteínas Quinases/uso terapêutico , Infecções por Protozoários/tratamento farmacológico , Proteínas de Protozoários/antagonistas & inibidores , Relação Estrutura-Atividade , Quinases Dyrk
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA